Tissue Repair Applies for ASX Removal Citing Low Liquidity and High Costs

Liquidity and Listing Costs Drive Delisting Proposal

Tissue Repair Limited (ASX:TRP) has formally applied to the Australian Securities Exchange for removal from the official list, marking a significant shift in its market presence. The board points to persistently low liquidity as a primary motivator, highlighting an average daily trading value of just $6,000 over the past 90 days. This thin trading volume has led to price volatility disproportionate to the company's actual value, undermining the ASX listing's utility as a price discovery mechanism.

Additionally, the company’s shareholding is concentrated among a small core of long-term investors, limiting free float and further suppressing market activity. A substantial number of shareholders hold unmarketable parcels, which the board argues receive limited benefit from the listing. These structural factors combine with an estimated $800,000 annual cost burden related to listing fees, compliance, and administration, costs deemed excessive relative to the company's size and stage.

Shareholder Approval and ASX Conditions Pending

The ASX has given in-principle support for the delisting, contingent on several conditions. Most notably, Tissue Repair must secure shareholder approval via a special resolution at a forthcoming general meeting. The delisting cannot proceed earlier than one month after this approval, ensuring shareholders have sufficient time to exit if they choose. The company plans to dispatch a detailed notice of meeting by 31 July 2026, with the meeting itself scheduled for 31 August 2026.

Further ASX conditions include providing shareholders with comprehensive information about the delisting process, suspending trading at least two business days before the delisting date, and meeting disclosure obligations under ASX Guidance Note 33. The indicative timetable targets removal from the official list by 26 October 2026.

Structured Buy-Back Offers Premium Exit Opportunity

To facilitate shareholder liquidity amid the impending loss of a public market, Tissue Repair proposes an off-market equal access share buy-back. The buy-back price is set at $0.13 per share, a premium to the recent volume weighted average price of approximately $0.11. The buy-back is capped at $1 million, representing about 12–13% of the company's issued capital, and will be funded from existing cash reserves.

The buy-back will be open for around four weeks following shareholder approval and before the delisting takes effect. If demand exceeds the buy-back size, acceptances will be scaled back pro rata to ensure fairness. Following the buy-back, an unmarketable parcel sale facility will be implemented to assist holders of small share parcels in realising value.

Post-Delisting Shareholder Implications and Governance

Once delisted, Tissue Repair shares will no longer be traded on the ASX, and shareholders wishing to transact will need to do so via private off-market arrangements, which lack guaranteed liquidity. Shareholders’ CHESS holdings will convert to issuer-sponsored holdings automatically, requiring no action.

The company will transition to an unlisted public company, relinquishing ASX listing rules and corporate governance requirements, but retaining obligations under the Corporations Act, including continuous disclosure and takeover provisions where applicable. The constitution remains unchanged, preserving shareholder rights to vote, receive notices, and dividends.

This move follows a period of clinical and commercial development for Tissue Repair, including ongoing Phase 3 trials and product rollouts, but the company’s share price and trading volumes have not reflected these underlying activities, raising questions about the efficacy of its public listing as a capital market vehicle.